Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this protocol is to provide continued acess to immunosuppressive medications to subjects from the completed/closed trial ITN005CT (NIS01,NCT00014911). THIS PROTOCOL DOES NOT PROVIDE MEDICINES TO DIABETES PATIENTS WHO DID NOT PARTICIPATE IN ITN005CT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539

Neurological Disorder Autoimmune Diseases

COMPLETED

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

NCT03298542

Pre-Symptomatic Type 1 Diabetes

COMPLETED PHASE1

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

NCT04182984

Ocular Myasthenia Gravis

RECRUITING

Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg

NCT01349270

Demyelinating Polyneuropathy

COMPLETED PHASE3

JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

NCT06797024

Autoimmune Diseases of the Nervous System

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study acronym: EXIIST - Extended Immunosuppression in Islet Transplantation

Islet transplantation is an experimental therapy in people with difficult to control Type 1 diabetes (T1D). Insulin producing cells (islets) are isolated from a pancreas. After the cells are prepared, the islets are put into the subject's liver. These transplanted islets may produce insulin that the subject's islets can no longer make. In order to help keep up the function of the transplanted islets, immunosuppressive medications must be given indefinitely or for as long as the study doctor determines is necessary. The medications serve to modify the immune system that normally tries to destroy (reject) new islets.

Participants in this study have received up to three islet cell infusions as a previous participant in the ITN005CT (NIS01) protocol. They also received a maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these immunosuppressive medications to subjects whose islets continue to function and make C-peptide.

Routine study follow-up visits will occur on an annual and -as warranted basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

Intervention Type DRUG

Tacrolimus

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

Intervention Type DRUG

Mycophenolate mofetil

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

Intervention Type DRUG

Mycophenolic acid

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rapamune® Prograf® MMF CellCept Myfortic®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participation in clinical trial ITN005CT (reference: ClinicalTrials.gov record NCT00014911) at Harvard University (Massachusetts General Hospital), Washington University, or University of Miami.
* Immunosuppressive regimen consisting of a single agent or some combination from among the following: tacrolimus, sirolimus, mycophenolate mofetil, and mycophenolic acid.
* Willingness of participants to use an approved method of contraception before, during, and 12 weeks after study participation.
* Peak C-peptide \>0.1 pmol/mL during a mixed meal tolerance test (MMTT) within 12 months of the screening visit.

Exclusion Criteria

* Inability to understand and sign the informed consent document for this study.
* Any medical condition which in the opinion of the investigator should preclude participation.
* Serum creatinine \> 1.6 mg/dL
* Insulin requirement \> 1.0 IU/kg/day
* Hemoglobin A1C (HbA1C) result \> 12%
* Hypoglycemia unawareness defined as the absence of adequate autonomic symptoms at plasma glucose levels of \< 54 mg/dL requiring treatment with glucagon, outside assistance, or treatment in an emergency room or hospital within a 12-month period

Eligible Sex

ALL

Accepts Healthy Volunteers

No